Newly‐developed nanoparticles with enhanced tumour penetration could overcome the biological barriers of the heavy desmoplastic reaction in the PDAC tumour microenvironment,56 and these nanoparticles targeting PTGS2 (COX‐2) expression in CD206+ TAMs would be predicted to have therapeutic benefits for PDAC patients. Here, MRC1 is linked to neoplasm.